PIK3CA-related Vascular Malformations (PRVM) Clinical Trials in Chengdu, Sichuan

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)